Table 1.
Baseline characteristics of patients with PLC treated with ICIs
| Characteristic | All patients (N = 172) |
|---|---|
| Age, mean ± SD | 51.4 ± 11.7 |
| Gender male, N (%) | 149(86.6) |
| Body mass index (kg/m2), median (IQR) | 22.2(20.0–24.2) |
| < 18.5 (underweight), N (%) | 22(12.8) |
| 18.5 ~ 24.9 (normal weight), N (%) | 113(65.7) |
| ≥ 25 (overweight), N (%) | 37(21.5) |
| Viral status, N (%) | |
| HCV/HBV/HCV + HBV/none | 3/153/2/14(1.7/89.0/1.2/8.1) |
| Alcohol consumption, N (%) | |
| > 80 g per day | 19(11.0) |
| Smoking status, N (%) | |
| Never/former/current | 101/19/52(58.7/11.0/30.2) |
| BCLC stage, N (%) | |
| B/C | 36/136(20.9/79.1) |
| ECOG-PS, N (%) | |
| 0/1/2/3 | 92/68/9/3(53.5/39.5/5.2/1.8) |
| Child-Pugh Class, N (%) | |
| A/B/C | 138/32/2(80.2/18.6/1.2) |
| Comorbidity, N (%) | |
| Hypertension (yes/no) | 35/137(20.3/79.7) |
| Diabetes (yes/no) | 20/152(12.2/87.8) |
| Liver Cirrhosis (yes/no) | 102/70(59.3/40.7) |
| Previous treatment (yes/no), N (%) | 154/18(89.5/10.5) |
| Baseline metastasis (yes/no), N (%) | 135/37(78.5/21.5) |
| Body composition variable | |
| SMI (cm2/m2), median (IQR) | 46.0(41.1–52.5) |
| SMD (HU), median (IQR) | 39.9(36.4–44.0) |
| VATI (cm2/m2), median (IQR) | 29.0(15.1–46.6) |
| SATI (cm2/m2), median (IQR) | 33.7(19.0–51.4) |
| TATI (cm2/m2), median (IQR) | 66.9(35.2–99.6) |
| VSR, median (IQR) | 0.84(0.59–1.19) |
PLC Primary liver cancer, ICI Immune checkpoint inhibitor, SD Standard deviation, IQR Interquartile range, HCV Hepatitis s C virus, HBV Hepatitis B virus, BCLC Barcelona Clinic Liver Cancer, ECOG Eastern Cooperative Oncology Group, PS Performance status, SMI Skeletal muscle index, SMD Skeletal muscle density, SMG Skeletal muscle gauge, VATI Visceral adipose tissue index, SATI Subcutaneous adipose tissue index, TATI Total adipose tissue index, VSR Visceral to subcutaneous fat area ratio